Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Universe Pharmaceuticals Inc. (UPC)
USD4.69
+0.07 (+1.49%)
CN NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 265, Jingjiu Avenue 343100
Ji'An, CN
Ji'An, CN
CEO
Gang Lai
Website
universe-pharmacy.com
IPO
2021-03-23
CIK 1809616 ISIN KYG9442G1385
Description
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.69
+0.07 (+1.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.60
Float Shares
491.5K
Free Float %
87.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +22.81% | +28.68% | +8.36% | +28.68% | -11.17% | -8.14% | -27.54% | -99.83% | -99.97% | -99.98% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.69
DCF (Unlevered)
6,974.26
+148,636.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
0.56
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-22.4% Q3'25: -37.1% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+26.5% ★ Q3'25: +99.9% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-32.3% Q3'25: -89.4% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-19.3% Q3'25: -3.3% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-10.8% Q3'25: -3.6% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-42.8% ★ Q3'25: +9,411.0% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-3.17× Q3'25: -63.91× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.84M
OE per share TTM
-2,795.49
Owner's Yield
-1,310.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
36.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
3.6K
Insider transactions (90d)
1
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gang Lai | 12.48M | 57.38% | — | 12.48M | — | 12.48M | IN | British Virgin Islands | 2022-02-11 | ↗ |
| 2 | Sununion Holding Group Limited | 12.48M | 57.38% | — | 12.48M | — | 12.48M | FI | British Virgin Islands | 2022-02-11 | ↗ |
| 3 | Efrem Kamen | 1.12M | 5.13% | — | 1.12M | — | 1.12M | HC, IN | Delaware | 2021-12-28 | ↗ |
| 4 | Pura Vida Investments, LLC | 1.12M | 5.13% | — | 1.12M | — | 1.12M | IA | Delaware | 2021-12-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | UBS GROUP AG | — -946.0 (-100.0%) | — -3.6K (-100.0%) | 0.00% -27.200 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Lai Gang | Director / Officer / 10% Owner | A-Award | A | Class A ordinary shares, par value US$0.00001 per share | 71,890 | 0.00 | — | 71,890 | D | ↗ |
| 2026-03-18 | Zheng Ding | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Yu Yongping | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Yang Lin (Lydia) | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Pang Jiawen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Liu Baochang | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Lai Gang | Director / Officer | — | — | Class B ordinary shares, par value US$0.00001 per share | 0 | 0.00 | — | 3,467 | I | ↗ |
| 2004-12-31 | WHITE JOHN V | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-12-31 | SCHENCK STEVE J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-12-31 | ROBERTS JOHN R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-12-31 | POYNTER LOU ANN | Director | — | I | Common Stock | 0 | 0.00 | — | 3,719 | — | ↗ |
| 2004-12-31 | MOORE JACKSON W | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-12-31 | HENRIQUES ADOLFO | Officer | — | I | Common Stock | 0 | 0.00 | — | 338 | — | ↗ |
| 2004-12-31 | HARTON LYNN | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-12-31 | AUSTIN ALBERT M | Director | — | I | Common Stock | 0 | 0.00 | — | 750 | — | ↗ |
| 2004-05-03 | WHITE JOHN V | Officer | M-Exempt | A | Common Stock | 9,364 | 19.17 | 179.5K | 81,923 | — | ↗ |
| 2004-04-21 | WHITE JOHN V | Officer | J-Other | A | Common Stock | 7 | 0.00 | — | 188 | — | ↗ |
| 2004-04-21 | SCHENCK STEVE J | Officer | J-Other | A | Common Stock | 28 | 0.00 | — | 661 | — | ↗ |
| 2004-04-21 | POYNTER LOU ANN | Director | J-Other | A | Common Stock | 38 | 0.00 | — | 906 | — | ↗ |
| 2004-04-21 | MOORE JACKSON W | Director / Officer | J-Other | A | Common Stock | 273 | 0.00 | — | 6,525 | — | ↗ |
| 2004-04-21 | HENRIQUES ADOLFO | Officer | J-Other | A | Common Stock | 28 | 0.00 | — | 671 | — | ↗ |
| 2004-04-21 | HARTON LYNN | Officer | J-Other | A | Common Stock | 126 | 0.00 | — | 126 | — | ↗ |
| 2004-04-07 | AUSTIN ALBERT M | Director | G-Gift | D | Common Stock | 1,213 | 0.00 | — | 2,426 | — | ↗ |
| 2004-01-27 | MOORE JACKSON W | Director / Officer | M-Exempt | D | Emp.Stock Option(right to buy) | 13,780 | 30.01 | 413.6K | 21,371 | — | ↗ |
| 2004-01-26 | SCHENCK STEVE J | Officer | M-Exempt | A | Common Stock | 17,230 | 22.92 | 394.9K | 87,188 | — | ↗ |
| 2004-01-23 | POYNTER LOU ANN | Director | M-Exempt | A | Common Stock | 33,334 | 24.81 | 827.0K | 143,266 | — | ↗ |
| 2004-01-15 | WHITE JOHN V | Officer | A-Award | A | Common Stock | 9,000 | 0.00 | — | 79,793 | — | ↗ |
| 2004-01-15 | SCHENCK STEVE J | Officer | A-Award | A | Common Stock | 9,000 | 0.00 | — | 82,428 | — | ↗ |
| 2004-01-15 | POYNTER LOU ANN | Director | A-Award | A | Common Stock | 7,500 | 0.00 | — | 147,140 | — | ↗ |
| 2004-01-15 | MOORE JACKSON W | Director / Officer | A-Award | A | Common Stock | 36,000 | 0.00 | — | 1,285,106 | — | ↗ |
| 2004-01-15 | HENRIQUES ADOLFO | Officer | A-Award | A | Common Stock | 9,000 | 0.00 | — | 80,887 | — | ↗ |
| 2004-01-14 | WHITE JOHN V | Officer | A-Award | A | Common Stock | 5,700 | 0.00 | — | 70,793 | — | ↗ |
| 2004-01-14 | SCHENCK STEVE J | Officer | A-Award | A | Common Stock | 5,700 | 0.00 | — | 73,428 | — | ↗ |
| 2004-01-14 | POYNTER LOU ANN | Director | A-Award | A | Common Stock | 4,800 | 0.00 | — | 139,640 | — | ↗ |
| 2004-01-14 | MOORE JACKSON W | Director / Officer | A-Award | A | Common Stock | 13,100 | 0.00 | — | 1,249,106 | — | ↗ |
| 2004-01-14 | HENRIQUES ADOLFO | Officer | A-Award | A | Common Stock | 6,800 | 0.00 | — | 71,887 | — | ↗ |
| 2004-01-14 | HARTON LYNN | Officer | A-Award | A | Common Stock | 3,900 | 0.00 | — | 8,200 | — | ↗ |
| 2004-01-06 | HARWOOD JAMES E | Director | J-Other | A | Common Stock | 4,082 | 0.00 | — | 74,689 | — | ↗ |
| 2004-01-02 | STARNES MICHAEL S | Director | A-Award | A | Emp.Stock Option(right to buy) | 7,900 | 31.21 | 246.6K | 7,900 | — | ↗ |
| 2004-01-02 | BARTHOLOMEW JR SAMUEL W | Director | A-Award | A | Emp.Stock Option(right to buy) | 7,900 | 31.21 | 246.6K | 7,900 | — | ↗ |
| 2003-12-31 | ROBERTS JOHN R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-12-31 | MOORE JACKSON W | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,236,006 | — | ↗ |
| 2003-12-31 | LEWIS PARNELL S JR | Director | — | D | Common Stock | 0 | 0.00 | — | 25,519 | — | ↗ |
| 2003-11-03 | WHITE JOHN V | Officer | A-Award | A | Emp.Stock Option(right to buy) | 1,708 | 33.69 | 57.5K | 1,708 | — | ↗ |
| 2003-10-16 | WHITE JOHN V | Officer | A-Award | A | Common Stock | 6,750 | 0.00 | — | 60,824 | — | ↗ |
| 2003-10-16 | MOORE JACKSON W | Director / Officer | J-Other | A | Common Stock | 32 | 0.00 | — | 27,119 | — | ↗ |
| 2003-10-15 | MOORE JACKSON W | Director / Officer | A-Award | A | Common Stock | 27,000 | 0.00 | — | 1,236,006 | — | ↗ |
| 2003-10-14 | WHITE JOHN V | Officer | A-Award | A | Emp.Stock Option(right to buy) | 93,750 | 33.48 | 3.14M | 93,750 | — | ↗ |
| 2003-10-14 | TRIPPEER RICHARD A JR | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 33.48 | 207.6K | 6,200 | — | ↗ |
| 2003-10-14 | STARNES MICHAEL S | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 33.48 | 207.6K | 6,200 | — | ↗ |
| 2003-10-14 | ROBERTS JOHN R | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 33.48 | 207.6K | 6,200 | — | ↗ |
| 2003-10-14 | PEREZ JORGE M | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 33.48 | 207.6K | 6,200 | — | ↗ |
| 2003-10-14 | MOORE JACKSON W | Director / Officer | A-Award | A | Emp.Stock Option(right to buy) | 412,500 | 33.48 | 13.81M | 412,500 | — | ↗ |
| 2003-10-14 | LEWIS PARNELL S JR | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 0.00 | — | 6,200 | — | ↗ |
| 2003-10-14 | HARWOOD JAMES E | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 33.48 | 207.6K | 6,200 | — | ↗ |
| 2003-10-14 | HARTON LYNN | Officer | A-Award | A | Common Stock | 4,300 | 0.00 | — | 4,300 | — | ↗ |
| 2003-10-14 | AUSTIN ALBERT M | Director | A-Award | A | Emp.Stock Option(right to buy) | 6,200 | 33.48 | 207.6K | 6,200 | — | ↗ |
| 2003-07-24 | SCHENCK STEVE J | Officer | A-Award | A | Emp.Stock Option(right to buy) | 514 | 32.04 | 16.5K | 1,540 | — | ↗ |
| 2003-07-17 | WHITE JOHN V | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-17 | SCHENCK STEVE J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-17 | POYNTER LOU ANN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-17 | MOORE JACKSON W | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-17 | HENRIQUES ADOLFO | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-08 | MOORE JACKSON W | Director / Officer | A-Award | A | Emp.Stock Option(right to buy) | 19,635 | 32.33 | 634.8K | 19,635 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-15.3K
Shares Outstanding
563.3K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baochang Liu | Chief Operating Officer | — | male |
| Gang Lai | Chief Executive Officer & Chairman | — | male |
| Lin Yang | Chief Financial Officer & Director | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UPC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
